NovoCure NVCR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $674.41M+8.5% | $655.35M+8.3% | $642.27M+11.2% | $630.16M+14.6% | $621.71M+18.3% | ||
| $167.29M+17.8% | $166.88M+21.6% | $158.19M+16.1% | $148.83M+11.9% | $142.01M+7.3% | ||
| $507.13M+5.7% | $488.47M+4.4% | $484.08M+9.7% | $481.33M+15.4% | $479.7M+22.0% | ||
| 75.2%-2.0pp | 74.5%-2.8pp | 75.4%-1.0pp | 76.4%+0.6pp | 77.2%+2.3pp | ||
| $229.1M+8.2% | $224.54M+7.1% | $214.85M+1.0% | $212.7M-0.8% | $211.82M-1.5% | ||
| $242.63M+1.2% | $240.06M+0.4% | $238.82M+3.5% | $240.1M+4.9% | $239.65M+3.8% | ||
| $218.75M+12.1% | $177.67M-6.4% | $207.13M+32.1% | $201.31M+26.9% | $195.07M+20.7% | ||
| $690.48M+6.8% | $642.27M+0.6% | $660.79M+10.1% | $654.11M+8.7% | $646.54M+6.4% | ||
| $690.48M+6.8% | $642.27M+0.6% | $660.79M+10.1% | $654.11M+8.7% | $646.54M+6.4% | ||
| -$183.36M-9.9% | -$153.8M+9.8% | -$176.71M-11.2% | -$172.78M+6.6% | -$166.84M+22.1% | ||
| -27.2%-0.4pp | -23.5%+4.7pp | -27.5%0.0pp | -27.4%+6.2pp | -26.8%+13.9pp | ||
| $8.7M-76.5% | $18.11M-54.0% | $26.21M-41.0% | $30.72M-30.1% | $37.03M-11.5% | ||
| -$175.21M-35.0% | -$136.25M-3.9% | -$150.5M-31.5% | -$142.07M-0.7% | -$129.82M+24.7% | ||
| -$2.17M-106% | -$23K-100% | $27.15M-23.1% | $28.89M+4.8% | $34.37M+68.2% | ||
| -$173.05M-5.4% | -$136.23M+19.2% | -$177.65M-18.6% | -$170.95M-1.3% | -$164.19M+14.8% | ||
| -25.7%+0.8pp | -20.8%+7.1pp | -27.7%-1.7pp | -27.1%+3.5pp | -26.4%+10.3pp | ||
| -$1.53-1.3% | -$1.22+21.8% | -$1.61-15.8% | -$1.56+0.6% | -$1.51+16.1% | ||
| -$1.53-1.3% | -$1.22+21.8% | -$1.61-15.8% | -$1.56+0.6% | -$1.51+16.1% | ||
| 449.1M+3.5% | 445.2M+3.3% | 441.6M+2.8% | 437.9M+2.3% | 434.1M+1.7% | ||
| 449.1M+3.5% | 445.2M+3.3% | 441.6M+2.8% | 437.9M+2.3% | 434.1M+1.7% | ||
| $8.7M-76.5% | $18.11M-54.0% | $26.21M-41.0% | $30.72M-30.1% | $37.03M-11.5% | ||
| -$183.36M-9.9% | -$153.8M+9.8% | -$176.71M-11.2% | -$172.78M+6.6% | -$166.84M+22.1% | ||
| -$167.91M-8.3% | -$139.15M+12.6% | -$163.18M-10.2% | -$160.45M+7.7% | -$155.1M+23.6% | ||
| -$167.91M-8.3% | -$139.15M+12.6% | -$163.18M-10.2% | -$160.45M+7.7% | -$155.1M+23.6% | ||
| -24.9%+0.1pp | -21.2%+5.1pp | -25.4%+0.2pp | -25.5%+6.2pp | -24.9%+13.7pp | ||
| -$183.36M-9.9% | -$153.8M+9.8% | -$176.71M-11.2% | -$172.78M+6.6% | -$166.84M+22.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is NovoCure's revenue?
- NovoCure (NVCR) generated $674.4M in revenue over the trailing twelve months, up 8.5% year over year.
- Is NovoCure profitable?
- NovoCure is not currently profitable: it reported a net loss of $173.0M over the trailing twelve months, a -25.7% net margin.
- What are NovoCure's profit margins?
- Gross margin is 75.2% and operating margin is -27.2%, with a -25.7% net margin.
- What is NovoCure's earnings per share?
- NovoCure's diluted EPS over the trailing twelve months is $-1.53.
- Where does NovoCure's income statement data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
